San Francisco, 28 January 2019: The Report Plasma Protein Therapeutic Market Size, Share & Trends Analysis Report By
Product (Albumin, Immunoglobulin, Factor VIII), By Application (Hemophilia,
PID, ITP), By Region, And Segment Forecasts, 2018 - 2025
The global plasma protein therapeutics market size is expected to reach USD 33.15 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 4.8% over the forecast period. The growth can be attributed to high prevalence of bleeding and other rare disorders, rising investment in R&D, and increasing use of plasma-derived products in neurology and other therapeutic indications.
Plasma-derived proteins are primarily used
as replacement therapies to treat chronic, rare diseases. Patients that rely on
these medications require regular injections or infusions throughout their
lives. While there are more than 250 products derived from plasma, key players
generally rely on Immunoglobulin (IG), albumin, and factor VIII to drive sales
and profitability.
Over the past decade, the plasma protein
therapeutics market has grown lucratively with immunoglobulin capturing the
major market share. Demand for plasma derived-products is driven by rising
disease prevalence, geriatric population, and improved access to drugs in
emerging markets. Approvals of new plasma-derived therapies are anticipated to
further fuel the demand. Developing countries such as China and Brazil offer
new investment avenues to the global market giants.
Access Research Report of Plasma Protein
Therapeutics Market @ www.grandviewresearch.com/industry-analysis/plasma-protein-therapeutic
Further key findings from the report suggest:
· Germany leads the European market,
supported by high demand for blood components, presence of key players, large
addressable population, and rising disease prevalence
· Demand for immunoglobulin is expected to
continue rising owing to prevalence of primary immunodeficiencies, usage in new
indications, and ease of administration
· Non-plasma based recombinant therapies are
likely to compete with plasma-derived products in the factor VIII market
· Asia Pacific is expected to exhibit high
growth over the forecast period fueled by increasing healthcare expenditure,
presence of a large number patients. improved ratio of patients suffering from
disease and patients receiving treatment, low-cost production of drugs, and
improvement in diagnostic technology.
· Major players operating in the plasma
protein therapeutics market include CSL Behring, Grifols, S.A., Shire Plc,
Octapharma AG, Biotest AG, and Kedrion S.P.A. Regional expansion, broad product
portfolio, and merger & acquisitions are chief strategic undertakings adopted
by key players.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/healthcare
Grand View Research has segmented the
global plasma protein therapeutics market on the basis of product, application,
and region:
Plasma Proteins Therapeutics Product
Outlook (Revenue, USD Million, 2014 - 2025)
·
Albumin
·
Immunoglobulin
·
Factor VIII
Plasma Proteins Therapeutics Application
Outlook (Revenue, USD Million, 2014 - 2025)
·
Hemophilia
·
Primary Immunodeficiency Disorder (PID)
·
Idiopathic Thrombocytopenic Purpura (ITP)
·
Others
Plasma Protein Therapeutics Regional
Outlook (Revenue, USD Million, 2014 - 2025)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East and Africa (MEA)
Access Press Release of
Plasma Protein Therapeutics Market@ www.grandviewresearch.com/press-release/global-plasma-protein-therapeutics-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment